NVCR vs SUPN

For growth investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger pick with 8. 6% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +60. 8%, compared to -92. 1% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SUPN returned +213. 7% versus NVCR's +40. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.

(SUPN) is the lower-risk stock at 0. 78β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 181% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Supernus Pharmaceuticals, Inc.

(SUPN) is pulling ahead at 8. 6% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Supernus Pharmaceuticals, Inc.

(SUPN) is the more profitable company, earning -5. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps -5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SUPN leads at -5. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 111.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78), +213. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SUPN: +213. 7%, NVCR: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.